Breast Cancer Clinical Trial
Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Breast Cancer
The purpose of the study is to see if the drug KU 0059436 (olaparib) is effective and well tolerated in treating patients with measurable BRCA1- or BRCA2-positive advanced breast cancer and for whom no curative therapeutic option exists
Advanced breast cancer with positive BRCA1 or BRCA2 status
Failed at least one prior chemotherapy
In investigators opinion, no curative standard therapy exists
Less than 28 days since last treatment used to treat the disease
Considered a poor medical risk due to a serious uncontrolled disorder
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 17 Locations for this study
West Hollywood California, 90048, United States
Boston Massachusetts, 02115, United States
Melbourne , 3000, Australia
Randwick , 2031, Australia
Duarte CA, 91010, Canada
Kiel , 24105, Germany
Köln , 50937, Germany
München , 81675, Germany
Tel-Aviv , 64239, Israel
Hospitalet deLlobregat , 08907, Spain
Madrid , 08035, Spain
Lund , 221 8, Sweden
Cambridge , CB2 0, United Kingdom
Edinburgh , EH4 2, United Kingdom
Fulham , SW3 6, United Kingdom
London , SE1 9, United Kingdom
Manchester , M20 4, United Kingdom
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.